iSpecimen Inc. ISPC
Biotechnology: Commercial Physical & Biological Resarch · IPO 2021 · data as of November 13, 2026
iSpecimen Inc. (ISPC) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to June 30, 2026 it had revenue of $466302 and net income of -$11M, a net margin of -2449.0%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -126%.
About iSpecimen
iSpecimen is listed in the US and classified in biotechnology: commercial physical & biological resarch, IPO year 2021. Revenue went from $8M in 2020 to $2M in 2025, a decline of about 25.1% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 941% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $466302 | $2M | $9M | $10M | $10M | $11M | $8M |
| Net income | -$11M | -$10M | -$12M | -$11M | -$10M | -$9M | -$5M |
| Free cash flow | — | -$4M | -$8M | -$6M | -$6M | -$11M | -$288806 |
| EPS (diluted) | $-2.48 | $-2.28 | $-17.58 | $-24.55 | $-23.20 | $-41.80 | $-99.40 |
| Net margin | -2449.0% | -543.7% | -134.5% | -111.8% | -98.5% | -80.5% | -56.8% |
| ROIC | — | -211.3% | -277.5% | -88.8% | -39.3% | -14.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does iSpecimen pay a dividend?
Not currently.
Is iSpecimen a good stock to buy?
We do not give buy or sell advice. iSpecimen scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.